Large Cap Archives - Page 140 of 437

1 minute read

Pricing Projections And Market Potential For Ionis’ Newly Approved Nerve Damage Drug – Analyst Sees Over $700M Potential

December 22, 1:04 PM

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

ALNY

2 minute read

Oil Prices Bag Second Straight Week Of Gains On Red Sea Turmoil, But They’re Still Off More Than 15% From 2023 Peak

By Neil Dennis

December 22, 12:33 PM

Gains come after seven straight weeks of losses - USO still down 16% from September peak.

2 minute read

Why Engine Manufacturer Cummins Shares Are Down Today

By Lekha Gupta

December 22, 10:37 AM

Cummins Inc (NYSE: CMI) shares are trading lower after it penned an agreement in principle to resolve the U.S.

CMI

2 minute read

Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal

By Vandana Singh

December 22, 10:19 AM

On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n

BMY

2 minute read

Palantir Office Blocked Over Israel Support, Stock Trades 24% Below 52-Week High — Are You Buying The Dip?

By Surbhi Jain

December 22, 10:01 AM

Protestors gathered at the Palantir UK office after its CEO reaffirmed that the data analytics firm is "supporting Israel in every way."

PLTR

1 minute read

Fake Ozempic – FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High Demand

By Vandana Singh

December 22, 8:52 AM

The FDA on Thursday said it continues to investigate counterfeit Novo Nordisk A/S's&n

NVO

1 minute read

New Hope for Nerve Damage Patients as AstraZeneca/Ionis’ Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment

By Vandana Singh

December 22, 8:49 AM

Friday, FDA approved AstraZeneca

AZN

1 minute read

Engineering Company AECOM Secures Vital Role In Eglinton Crosstown West Extension Project

By Lekha Gupta

December 22, 8:41 AM

AECOM (NYSE: ACM) disclosed being selected by Metrolinx as its delivery partner for the Eglinton Crosstown

ACM

1 minute read

TotalEnergies’ Windfall: $689M Seagreen Stake Sale Ignites Renewables Partnership In Thailand

By Lekha Gupta

December 22, 7:38 AM

TotalEnergies SE (NYSE: TTE) penned a deal with the national oil and gas company PTTEP in Thailand for

LYB

2 minute read

Argenx’s Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes

By Vandana Singh

December 21, 3:41 PM

Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and

ARGX